Navigation Links
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
Date:3/16/2008

human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company received FDA approval for two products: Cumulase(R) and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

This release includes forward-looking statements concerning the company's plans to initiate Phase III trials of the subcutaneous administration of GAMMAGARD LIQUID alone and with Enhanze Technology and expectations regarding the availability of the results related thereto. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: timely submission and approval of anticipated regulatory filings; the ability of the company to enroll a sufficient number of qualified participants in the proposed Phase III trials; the ability of the company to otherwise successfully initiate the Phase III trials; the ability of the company to complete the Phase III trials or any of them on a timely basis; and other risks discussed in the company's filings with the Securities and Exchange Commission (SEC) that could cause actual results to differ materially from those in the forward-looking statements. The company's SEC filings are available on its website. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changes assumptions or otherwise, and all forward- looking statements speak only as of the time when made. Actual results or experience could differ materially from the expectations contained in the forward-looking statements.

GAMMAGARD LIQUID and KIOVIG are trademarks of Baxter Hea
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
2. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
7. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
(Date:7/11/2014)... According to a new ... Material, Application (Healthcare, Homeland security, Industrial application, Nuclear ... Hand-Held Instruments, Fixed, and Installed Instruments) & Geography ... by MarketsandMarkets, the Scintillator Market is expected to ... to 2020, and reach $479.16 Million in 2020. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
... CAMBRIDGE, England, 26th April 2007 - CeNeS Pharmaceuticals ... that the United States Food and Drug Administration ... for the,clinical development of morphine-6-glucuronide (M6G), its novel,drug ... year,CeNeS announced results of a Phase III study ...
... April 20,2007-The U.S. Food and Drug,Administration (FDA) is ... of audio broadcasts that provide,emerging drug safety information. ... to personal computers and personal,audio players. , The ... to broaden,and speed its communications concerning the ...
Cached Medicine Technology:FDA approves IND on Lead Product M6G 2FDA Announces Audio Broadcasts on Emerging Drug Safety Information 2
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most ... outfits, has released its new range of elegant ... are available at discounted prices. Worldwide clients can enjoy ... In the company’s online shop, there are plenty of ... made with great materials. MyDressCity.com’s hot items are prom ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
(Date:7/13/2014)... A decreased ability to identify odors might indicate ... while examinations of the eye could indicate the ... in the brain, according to the results of ... Association International Conference 2014 (AAIC 2014) in Copenhagen. ... ability to identify odors was significantly associated with ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... Lipitor bellwether trial has been scheduled in July of ... The Lipitor lawsuits are in the discovery process ... Judge Richard M. Gergel is presiding over the multidistrict ... were filed on behalf of individuals who allege that ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... OAKLAND, Calif., Feb. 7 Nytera Tilmon works,at ... for her seven children,all of whom live with asthma. ... new television show revealing Nytera,s story and others,behind the ... "Union Time" and it,s the only national labor-produced TV ...
... Mass., USA (February 7, 2008) After just seven months ... been named the 2007 Best New Journal - Science, Technology ... of the Association of American Publishers (AAP). , This honor, ... for Excellence, comes less than a year after Cell Stem ...
... Transcept Pharmaceuticals,Inc. today announced that Glenn A. ... the 10th Annual BIO CEO & Investor Conference ... Tuesday, February 12, 2008 at,10:15 AM Eastern Time., ... is a specialty pharmaceutical company,deriving significant new patient ...
... March Meeting of American Physical Society will take place March ... scientists are expected to be on hand. The principal ... materials, chemical and biological physics, fluids, polymers, and computation. , ... is both a great showcase for fundamental physics research and ...
... Owners and employees agree that the rising ... WASHINGTON, Feb. 7 Post-primary polling,shows small-business ... voting,segment equal to, and larger than, well-established ... The National Federation of Independent Business (NFIB), ...
... by the body can make the difference between your average ... the United States last year, reveals a new study in ... of Cell Press. , If this natural anti-cancer agent, ... might serve as a targeted chemotherapy for metastatic melanoma, a ...
Cached Medicine News:Health News:Cell Stem Cell named 'Best New Journal' of 2007 2Health News:Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Health News:Physics breakthroughs on tap at New Orleans conference 2Health News:Small Business Turns Out on Super Tuesday 2Health News:Small Business Turns Out on Super Tuesday 3Health News:Natural secretion marks difference between mole and melanoma 2Health News:Natural secretion marks difference between mole and melanoma 3
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
Gently curved shafts with pierse tips. Round, knurled handle for finger tip rotation. Excellent for atramatic grasp of corneal flap. Made in titanium....
Narrow 12 mm jaws with fine teeth. Serrated handle with polished finish....
Straight shafts with curved 1 x 2 teeth. Serrated handle with polished finish....
Medicine Products: